Cancer Communications
indexed by SCI
BMC

Original Article
Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis
Jun-Fang Liao,Qun Zhang, Xiao-Jing Du, Mei Lan, Shan Liu, Yun-Fei Xia, Xiu-Yu Cai and Wei Luo
Department of Radiation Oncology, National Cancer Center/Cancer Hospital & Shenzhen Hospital, Shenzhen, 518116, Guangdong, P. R. China
[Abstract]

Background
Promising efficacy and manageable toxicity of docetaxel-based concurrent chemoradiotherapy (CCRT) were reported in head and neck cancer. In addition, the effect of CCRT in combination with cisplatin and/or 5-fluorouracil on both locoregionally advanced and metastatic/recurrent nasopharyngeal carcinoma (NPC) was verified. However, CCRT with docetaxel for locoregionally advanced NPC are not well studied. This study aimed to compare effectiveness and toxicities of CCRT with weekly docetaxel versus tri-weekly cisplatin for locoregionally advanced NPC.
Methods
Clinical data of patients with locoregionally advanced NPC newly diagnosed between January 2010 and December 2014 receiving CCRT with either weekly docetaxel (15 mg/m2) or tri-weekly cisplatin (80–100 mg/m2) were reviewed. Propensity score matching at a 1:1 ratio was performed to balance baseline characteristics. Adverse events and survival were compared between the two groups.
Results
A total of 962 patients were included as the whole cohort, and 448 patients were matched and were regarded as the matched cohort. The median follow-up duration was 48 months for the whole cohort. The 3-year nodal recurrence-free survival rate was significantly increased for patients treated with docetaxel in both the whole (hazard ratio [HR]?=?0.37, 95% confidence interval [CI] 0.19–0.72, P?=?0.030) and matched cohorts (HR?=?0.33, 95% CI 0.14–0.79, P?=?0.023). However, no significant differences were observed in overall survival, local recurrence-free survival, and distant metastasis-free survival between the two groups in both cohorts. Significantly higher rates of grade 3 radiodermatitis (6.7% vs. 1.8%, P?=?0.001), mucositis (74.5% vs. 37.9%, P?Conclusions
CCRT with weekly low-dose docetaxel is an effective and tolerable therapeutic regimen for locally advanced NPC. It provides a survival benefit mainly by improving the control of regional lymph node metastases, especially for patients with low pretreatment EBV DNA levels.
Cancer Communications   Epub date: 6/29/2019   doi:10.1186/s40880-019-0380-x
[PDF Full-text]

[ Html full-text] (BioMed Central)

[ PubMed]

Cite this article

Jun-Fang Liao,Qun Zhang, Xiao-Jing Du, Mei Lan, Shan Liu, Yun-Fei Xia, Xiu-Yu Cai and Wei Luo. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis. Cancer Commun (Lond). 2019, 39:40. doi:10.1186/s40880-019-0380-x


Export citations

EndNote

CJC Wechat 微信公众号


 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by BioMed Central

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China